Indications for Use
Somryst® is a prescription-only digital therapeutic intended to provide a neurobehavioral intervention (CBT-I) to patients 22 years of age and older with chronic insomnia. Somryst treats patients with chronic insomnia by improving a patient’s insomnia symptoms.
Who Should Use Somryst?
You should use Somryst if you:
- Are 22 or older with chronic insomnia
- Are able to read and understand English
- Have regular access to a mobile device (such as smartphone or tablet)
- Are familiar with how to use mobile apps (applications)
- Are able to upload data periodically. (In other words, you have internet/wireless connection access.)
- Are under the supervision of a Health Care Provider
Who Should Not Use Somryst® (Contraindications)
Somryst uses sleep restriction and consolidation, limiting the time you spend in bed to match the amount of time you sleep. Sleep restriction and consolidation may worsen preexisting medical conditions. Because of this, it is not appropriate for everyone.
If you have any of the following conditions or disorders, you should not use Somryst:
- Any disorder worsened by sleep restriction (e.g. bipolar disorder, schizophrenia, other psychotic spectrum disorders)
- Untreated obstructive sleep apnea
- If you are at high risk of falls
- If you are pregnant
- If you have any other unstable or degenerative illness judged to be worsened by sleep restriction delivered as part of Cognitive Behavioral Therapy for Insomnia
If you are unsure whether you have any of the conditions or disorders listed, speak with your Health Care Provider.
Somryst® is not for everyone. You and your Health Care Provider should discuss whether Somryst is right for you.
- Somryst is not for emergency use. Please dial 911 or go to the nearest emergency room in the event of a medical emergency.
- Do not use Somryst to communicate severe or urgent information to your Health Care Provider.
- Somryst is not meant to be used as treatment except under supervision of your Health Care Provider.
- Somryst is not meant to be a substitution for any treatment medication.
- Somryst contains sensitive medical information about you. It is important that you protect your information by password-protecting your smartphone or tablet and ensuring no one else has access to your device.
Sleep Restriction (and Consolidation) within Somryst can cause sleepiness, especially in the early stages of using the PDT. Somryst should not be used if you need to be alert or cautious to avoid serious accidents in your job or daily life. Examples include:
— Long-haul truck drivers— Long-distance bus drivers— Air traffic controllers— Operators of heavy machinery— Some assembly line jobs
- The usage data collected in therapy lessons by Somryst are not intended to be used as a standalone assessment of treatment progress.
In the early stages of treatment, increased daytime sleepiness may be expected, but is usually temporary. However, if these experiences do not go away over a few weeks, please consult your health care provider as you may have a sleep disorder or medical condition other than insomnia. Also, at any point in the treatment, if you have trouble staying awake while performing potentially dangerous tasks (like driving) avoid these tasks or stop following the sleep restriction component of the therapy.
For best results with Somryst, read and follow the instructions provided in each core, and stay with the therapy until the end. When reporting your sleep results, giving honest and accurate answers is important.
Care Regimen and Self-care
Following your Health Care Provider’s instructions for care is always important. If you need help managing your condition, speak with your Health Care Provider.
Disclaimer: No user or party is compensated for prescribing Somryst or for being included in this list. Pear Therapeutics is not liable or responsible for any diagnosis, treatment decision, or other decisions made up by the providers and/or facilities listed.
This tool is updated on an ongoing basis to reflect our most up-to-date list of providers and facilities currently prescribing Somryst.
If you are a provider or facility that is interested in prescribing Somryst, or to learn more, please contact 1-833-697-3738.
References: 1. Insomnia. Mayo Clinic. Accessed May 19, 2022. https://www.mayoclinic.org/diseases-conditions/insomnia/symptoms-causes/syc-20355167 2. Anderson KN. Insomnia and cognitive behavioural therapy-how to assess your patient and why it should be a standard part of care. J Thorac Dis. 2018;10(Suppl 1):S94-S102. doi:10.21037/jtd.2018.01.35. 3. Feuerstein S, Hodges SE, Keenaghan B, Bessette A, Forselius E, Morgan PT. Computerized Cognitive Behavioral Therapy for Insomnia in a Community Health Setting. J Clin Sleep Med. 2017;13(2):267-274. doi:10.5664/jcsm.6460. 4. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125-33. doi: 10.7326/M15-2175. 5. Substance Abuse and Mental Health Services Administration. (2016). Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health. CBHSQ Methodology Report. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD. Accessed May 19, 2022. https://www.ncbi.nlm.nih.gov/books/NBK519697/ 6. QuickFacts United States. US Census Bureau. Accessed May 19, 2022. https://www.census.gov/quickfacts/fact/table/US# 7. Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, Sateia MJ, Troxel WM, Zhou ES, Kazmi U, Heald JL, Martin JL. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255-262. doi: 10.5664/jcsm.8986. PMID: 33164742; PMCID: PMC7853203.